Ahit, Zia Dexzie P.
HRN: 21-83-18 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/06/2025
OXACILLIN 500MG (VIAL)
05/06/2025
05/12/2025
IV
400mg
Q6
Impetigo
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes